DexCom (NASDAQ:DXCM) Price Target Cut to $75.00 by Analysts at TD Cowen

DexCom (NASDAQ:DXCM) had its price objective lowered by TD Cowen from $84.00 to $75.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. TD Cowen’s price target would suggest a potential upside of 22.74% from the company’s current price.

DXCM has been the subject of several other reports. Citigroup upped their target price on DexCom from $77.00 to $84.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Canaccord Genuity Group set a $100.00 target price on DexCom in a report on Friday. Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price for the company in a report on Tuesday, March 24th. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, Barclays set a $67.00 price target on DexCom and gave the company an “underweight” rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $83.73.

DexCom Trading Up 2.6%

NASDAQ:DXCM traded up $1.55 during trading hours on Friday, hitting $61.10. The company had a trading volume of 7,990,597 shares, compared to its average volume of 4,896,271. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The company has a 50-day moving average of $65.87 and a 200 day moving average of $66.40. The company has a market cap of $23.58 billion, a P/E ratio of 29.10, a P/E/G ratio of 1.12 and a beta of 1.55. DexCom has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.32 EPS. Sell-side analysts expect that DexCom will post 2.49 earnings per share for the current year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DexCom

Several hedge funds have recently bought and sold shares of the company. Sequoia Financial Advisors LLC lifted its stake in DexCom by 14.2% during the 1st quarter. Sequoia Financial Advisors LLC now owns 16,607 shares of the medical device company’s stock worth $1,043,000 after acquiring an additional 2,062 shares in the last quarter. Fulcrum Capital LLC lifted its stake in DexCom by 8.9% during the 1st quarter. Fulcrum Capital LLC now owns 44,740 shares of the medical device company’s stock worth $2,810,000 after acquiring an additional 3,654 shares in the last quarter. Peterson Wealth Services lifted its stake in DexCom by 68.7% during the 1st quarter. Peterson Wealth Services now owns 9,347 shares of the medical device company’s stock worth $587,000 after acquiring an additional 3,808 shares in the last quarter. Azzad Asset Management Inc. ADV lifted its stake in DexCom by 3.1% during the 1st quarter. Azzad Asset Management Inc. ADV now owns 13,881 shares of the medical device company’s stock worth $872,000 after acquiring an additional 419 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. lifted its stake in DexCom by 1.2% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 124,031 shares of the medical device company’s stock worth $7,766,000 after acquiring an additional 1,448 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 beat on both EPS and revenue, with revenue up ~15% YoY and non?GAAP EPS of $0.56 beating estimates; margins expanded, driving the bullish near?term reaction. DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
• Positive Sentiment: Analysts remain constructive: BTIG reaffirmed a Buy rating (cut PT modestly), and broker consensus price targets (~$86.50) sit well above the current share price, supporting upside potential. BTIG Remains Bullish on DexCom, Inc. (DXCM)
• Positive Sentiment: Management highlighted strong international demand and product launches as growth drivers and provided a profitability outlook that investors interpreted as improving operating leverage. DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights
• Neutral Sentiment: Company reaffirmed its FY26 revenue forecast (roughly $5.2–5.3B), meaning management did not raise guidance despite the beat; this is neutral-to-mixed since it signals caution while keeping expectations in line. Dexcom reaffirms full-year forecast after topping quarterly estimates
• Neutral Sentiment: Full earnings materials and transcripts are available for deeper scrutiny (useful for investors wanting management color on US vs. international trends and product cadence). Investor Slide Deck / Press Release
• Negative Sentiment: Management cited the “current geopolitical environment” as a reason for not raising FY26 revenue guidance, which injected caution and helped trigger an after?hours selloff despite the beat. Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook
• Negative Sentiment: Some market reports noted an immediate post?earnings decline as investors focused on guidance conservatism rather than the beat—an indicator of how forward guidance, not just current results, is driving stock moves. Dexcom falls over 5% despite better?than?expected Q1 print, as revenue guidance disappoints

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.